We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+3.78%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$151M
AUM Growth
+$23M
Cap. Flow
+$26.2M
Cap. Flow %
17.3%
Top 10 Hldgs %
42.26%
Holding
109
New
25
Increased
23
Reduced
25
Closed
15

Top Buys

Rank Stock Value
1
BCAX
Bicara Therapeutics
BCAX
+$2.4M
2
PVLA
Palvella Therapeutics
PVLA
+$2.24M
3
ZBIO
Zenas BioPharma
ZBIO
+$2.05M
4
REPL icon
Replimune Group
REPL
+$2.02M
5
TECX
Tectonic Therapeutic
TECX
+$2.01M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$2.14M
2
GILD icon
Gilead Sciences
GILD
+$1.31M
3
THC icon
Tenet Healthcare
THC
+$1.21M
4
SWTX
SpringWorks Therapeutics
SWTX
+$1.12M
5
BPMC
Blueprint Medicines
BPMC
+$994K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
76
Scholar Rock
SRRK
$5.64B
$368K 0.24%
+10,380
New +$326K
IONS icon
77
Ionis Pharmaceuticals
IONS
$8.57B
$364K 0.24%
9,205
-235
-2% -$7.69K
RPRX icon
78
Royalty Pharma
RPRX
$25.9B
$334K 0.22%
9,280
– –
BIIB icon
79
Biogen
BIIB
$30B
$298K 0.2%
2,375
-480
-17% -$59.8K
ILMN icon
80
Illumina
ILMN
$29.7B
$265K 0.18%
2,782
-900
-24% -$73K
JAZZ icon
81
Jazz Pharmaceuticals
JAZZ
$15.8B
$241K 0.16%
2,274
– –
TEM
82
Tempus AI
TEM
$7.67B
$239K 0.16%
3,760
+1,600
+74% +$91.7K
RVMD icon
83
Revolution Medicines
RVMD
$40.1B
$230K 0.15%
6,240
– –
CAI
84
Caris Life Sciences
CAI
$4.34B
$223K 0.15%
+8,350
New +$225K
MDGL icon
85
Madrigal Pharmaceuticals
MDGL
$10.8B
$221K 0.15%
730
– –
UTHR icon
86
United Therapeutics
UTHR
$25.7B
$220K 0.15%
765
– –
VTRS icon
87
Viatris
VTRS
$20.3B
$177K 0.12%
19,800
– –
MEDP icon
88
Medpace
MEDP
$16B
$167K 0.11%
531
– –
IOBT
89
DELISTED
IO Biotech
IOBT
$164K 0.11%
117,691
+22,691
+24% +$26K
MRNA icon
90
Moderna
MRNA
$22.9B
$155K 0.1%
5,600
– –
PCVX icon
91
Vaxcyte
PCVX
$7.83B
$137K 0.09%
4,205
-16,835
-80% -$552K
CRSP icon
92
CRISPR Therapeutics
CRSP
$4.7B
$124K 0.08%
2,540
– –
AXSM icon
93
Axsome Therapeutics
AXSM
$11.4B
$106K 0.07%
1,020
– –
RXRX icon
94
Recursion Pharmaceuticals
RXRX
$1.59B
$58.2K 0.04%
11,500
– –
ARVN icon
95
Arvinas
ARVN
$517M
– –
-12,930
Closed -$90.8K
BPMC
96
DELISTED
Blueprint Medicines
BPMC
– –
-11,235
Closed -$994K
CLOV icon
97
Clover Health Investments
CLOV
$2.21B
– –
-183,000
Closed -$657K
COGT icon
98
Cogent Biosciences
COGT
$6.79B
– –
-79,020
Closed -$473K
CRNX icon
99
Crinetics Pharmaceuticals
CRNX
$8.86B
– –
-5,710
Closed -$192K
ELV icon
100
Elevance Health
ELV
$81.1B
– –
-1,500
Closed -$652K
1 2 3
4
5

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Sectoral Asset Management held 109 positions worth $151M, up 18% from $128M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sectoral Asset Management deployed $26.2M of net new capital in Q2 2025, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was Bicara Therapeutics: 201,395 shares worth $1.87M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $1.31M trimmed.

  • Sectoral Asset Management's largest Q2 2025 buy was Bicara Therapeutics: 201,395 shares worth $1.87M.
  • Sectoral Asset Management added most to Arcus Biosciences in Q2 2025, an estimated $1.97M increase.
  • Sectoral Asset Management's biggest Q2 2025 reduction was Gilead Sciences, cutting an estimated $1.31M.
  • Sectoral Asset Management fully exited Medtronic in Q2 2025, selling an estimated $2.14M.
  • Sectoral Asset Management's ten largest holdings make up 42% of its $151M portfolio in Q2 2025.
  • Sectoral Asset Management opened 25 new positions and closed 15 in Q2 2025.
  • Sectoral Asset Management's portfolio value rose 18% quarter-over-quarter to $151M.

Based on Sectoral Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.